Form 4: Invivyd Director Acquires Stock Options

Invivyd, Inc. director Tamsin Berry has acquired 50,000 stock options with an exercise price of $1.04, vesting in full by May 2027.

Summary

• Director Tamsin Berry acquired 50,000 stock options in Invivyd, Inc. on May 19, 2026.
• The options have an exercise price of $1.04 per share.
• These options are set to vest in full on the earlier of May 19, 2027, or the date of the Issuer's 2027 Annual Meeting of Stockholders, contingent upon Berry's continued service.
• The filing also includes a Limited Power of Attorney appointing several individuals to act on behalf of Tamsin Berry for Section 16 and Rule 144 reporting obligations.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily details routine insider transactions (grant of stock options) rather than significant financial results or strategic shifts.

Positives

• Director Tamsin Berry's acquisition of stock options indicates a commitment to the company's future performance.
• The exercise price of $1.04 suggests the options were granted at a price reflecting current or near-term market value, potentially aligning management incentives with shareholder value.
• The vesting schedule ties the full vesting to a future date (May 2027) or the 2027 Annual Meeting, encouraging long-term engagement.

Risks

• The value of the stock options is directly tied to the future stock price of Invivyd, Inc. If the stock price does not increase above the exercise price of $1.04, the options may not be exercised profitably.
• The vesting is contingent on continuous service, meaning any departure from the company before the vesting date would result in forfeiture of the unvested options.

Future Outlook

The stock options granted to Tamsin Berry are exercisable until May 18, 2036, and vest in full by May 19, 2027, or the 2027 Annual Meeting, subject to continued service. This indicates a forward-looking incentive tied to the company's performance over the next few years.

Industry Context

StockSavvy.ai notes that the granting of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors, aligning executive incentives with long-term company growth and shareholder value creation. The specific terms of the options, including the exercise price and vesting schedule, are crucial for assessing their potential impact on executive compensation and company performance.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of options to a director aligns management incentives with shareholder interests, potentially driving future stock price appreciation. However, the dilutive effect of future option exercises should be considered.
• Employees: The continued service requirement for vesting reinforces employee retention efforts, as key personnel are incentivized to remain with the company.
• Management: The options provide a potential financial reward for Tamsin Berry, contingent on her continued role and the company's success.

Next Steps

• Tamsin Berry must maintain continuous service through the vesting date to fully acquire the granted stock options.
• The company will continue to file Section 16 reports for any future transactions by its officers and directors.

Key Dates

Keywords

Invivyd, IVVD, Form 4, Stock Options, Director, Beneficial Ownership, Securities Exchange Act, Rule 10b5-1, Insider Trading, Vesting Schedule